Tarsus Pharmaceuticals Statistics
Total Valuation
TARS has a market cap or net worth of $1.78 billion. The enterprise value is $1.54 billion.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TARS has 38.23 million shares outstanding. The number of shares has increased by 30.92% in one year.
| Current Share Class | 38.23M |
| Shares Outstanding | 38.23M |
| Shares Change (YoY) | +30.92% |
| Shares Change (QoQ) | +1.48% |
| Owned by Insiders (%) | 8.62% |
| Owned by Institutions (%) | 100.39% |
| Float | 29.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 13.04 |
| Forward PS | 7.40 |
| PB Ratio | 7.49 |
| P/TBV Ratio | 7.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.42, with a Debt / Equity ratio of 0.31.
| Current Ratio | 5.42 |
| Quick Ratio | 5.27 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.54 |
Financial Efficiency
Return on equity (ROE) is -59.56% and return on invested capital (ROIC) is -31.58%.
| Return on Equity (ROE) | -59.56% |
| Return on Assets (ROA) | -27.26% |
| Return on Capital (ROIC) | -31.58% |
| Revenue Per Employee | $531,234 |
| Profits Per Employee | -$550,586 |
| Employee Count | 244 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 41.20 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +146.98% in the last 52 weeks. The beta is 1.00, so TARS's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | +146.98% |
| 50-Day Moving Average | 38.71 |
| 200-Day Moving Average | 33.07 |
| Relative Strength Index (RSI) | 62.25 |
| Average Volume (20 Days) | 1,030,138 |
Short Selling Information
The latest short interest is 8.16 million, so 21.34% of the outstanding shares have been sold short.
| Short Interest | 8.16M |
| Short Previous Month | 9.68M |
| Short % of Shares Out | 21.34% |
| Short % of Float | 28.12% |
| Short Ratio (days to cover) | 11.42 |
Income Statement
In the last 12 months, TARS had revenue of $129.62 million and -$134.34 million in losses. Loss per share was -$3.70.
| Revenue | 129.62M |
| Gross Profit | 70.69M |
| Operating Income | -140.60M |
| Pretax Income | -150.07M |
| Net Income | -134.34M |
| EBITDA | -139.46M |
| EBIT | -140.60M |
| Loss Per Share | -$3.70 |
Full Income StatementBalance Sheet
The company has $316.95 million in cash and $73.58 million in debt, giving a net cash position of $243.37 million or $6.37 per share.
| Cash & Cash Equivalents | 316.95M |
| Total Debt | 73.58M |
| Net Cash | 243.37M |
| Net Cash Per Share | $6.37 |
| Equity (Book Value) | 237.48M |
| Book Value Per Share | 6.22 |
| Working Capital | 291.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$100.18 million and capital expenditures -$1.50 million, giving a free cash flow of -$101.68 million.
| Operating Cash Flow | -100.18M |
| Capital Expenditures | -1.50M |
| Free Cash Flow | -101.68M |
| FCF Per Share | -$2.66 |
Full Cash Flow StatementMargins
Gross margin is 54.53%, with operating and profit margins of -108.47% and -103.64%.
| Gross Margin | 54.53% |
| Operating Margin | -108.47% |
| Pretax Margin | -103.64% |
| Profit Margin | -103.64% |
| EBITDA Margin | -107.59% |
| EBIT Margin | -108.47% |
| FCF Margin | -155.30% |
Dividends & Yields
TARS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -30.92% |
| Shareholder Yield | -30.92% |
| Earnings Yield | -7.54% |
| FCF Yield | -5.71% |
Analyst Forecast
The average price target for TARS is $54.20, which is 16.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $54.20 |
| Price Target Difference | 16.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 112.46% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TARS has an Altman Z-Score of 3.01 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.01 |
| Piotroski F-Score | 3 |